Statement: the primary trial and the secondary trial both administer Paclitaxel and Gemcitabine to their patients cohorts, but only the secondary trial utilises positron emission tomography.
Primary_evidence: INTERVENTION 1:    Treatment Schedule (Weekly)   Arm C, Docetaxel and Gemcitabine (Weekly):   Docetaxel: 30 mg/m², 30-60 min IV infusion on Days 1, 8, and 15 to be given 30 minutes prior to Gemcitabine, repeated every 28 days (weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.   Gemcitabine: 800 mg/m², 30 min IV infusion on Days 1, 8, and 15 repeated every 28 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.   Arm D, Paclitaxel and Gemcitabine (Weekly):   Paclitaxel: 80 mg/m², IV infusion over approximately 1 hour, Days 1, 8, and 15, followed by Gemcitabine, repeated every 28 days (weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.   Gemcitabine: 800 mg/m², 30 min IV infusion on Days 1, 8, and 15 repeated every 28 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD. INTERVENTION 2:    Treatment Schedule (3 Weekly)   Arm A, Docetaxel and Gemcitabine (3 Weekly):   Docetaxel: 75 mg/m², 60 min IV infusion on Day 1 only, to be given 30 min prior to Gemcitabine, repeated every 21 days (tri-weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.   Gemcitabine: 1000 mg/m², 30 min IV infusion on Days 1 and 8, repeated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.   Arm B, Paclitaxel and Gemcitabine (3 Weekly):   Paclitaxel: 175 mg/m², IV infusion over approximately 3 hours followed by Gemcitabine, repeated every 21 days (tri-weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.   Gemcitabine: 1250 mg/m², 30 min IV infusion on Days 1 and 8, repeated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.
Secondary_evidence: INTERVENTION 1:    Treatment (Enzyme Inhibitor Therapy, AI Sensitization Therapy)   Patients receive vorinostat PO QD for 2 weeks followed by AI therapy comprising anastrozole PO QD, letrozole PO QD, OR exemestane PO QD for 6 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.   vorinostat: Given PO   laboratory biomarker analysis: Correlative studies   biopsy: Optional correlative studies   F-18 16 alpha-fluoroestradiol: Correlative studies   positron emission tomography: Correlative studies   anastrozole: Given PO   letrozole: Given PO   exemestane: Given PO   gene expression analysis: Correlative studies